Exosome Biologics and UCT-MSC Stem Cell Suppliers in Texas: What Licensed Practitioners Need to Know

By Stem Nova Network · Spring, TX · April 2026 · For Licensed Medical Professionals Only · Not Legal Advice

Texas is one of the most active states in the country for regenerative medicine. With a large and growing licensed practitioner base across Houston, Dallas, Austin, San Antonio, and the surrounding metro areas — and an active legislative framework for stem cell biologic access — Texas physicians and medical professionals are increasingly evaluating exosome biologics and UCT-MSC stem cells as adjunct options for their practices.

This guide covers what Texas licensed practitioners need to know: the current legal framework under Texas law, how to evaluate a compliant supplier, the practice verticals where these biologics are most commonly used in Texas, and why sourcing from a Texas-based, AATB-accredited supplier matters. This is a regulatory and sourcing reference only — not clinical guidance or legal advice.

The Texas Legal Framework for Stem Cell Biologics

Texas has two active pieces of legislation that create pathways for licensed physicians to use non-FDA-approved stem cell biologics under defined conditions. Understanding both is essential before sourcing or administering these products in a Texas practice.

HB 810 — Charlie's Law (2017, as amended)

Texas House Bill 810, known as Charlie's Law, extended the state's Right to Try framework — originally created for terminal patients — to patients with severe chronic illness for adult stem cell biologics specifically. This created a separate, stem-cell-specific access pathway that operates alongside but distinct from federal Right to Try law.

Under HB 810 as it applies to stem cell biologics, the key requirements are:

• ✓Licensed physician — the administering provider must be a licensed physician (MD or DO) in the state of Texas
• ✓Eligible patients — patients must have a severe chronic disease or terminal illness
• ✓Clinical trial basis — the stem cell treatment must have been tested on humans in a clinical trial (not required to be a U.S. trial)
• ✓IRB oversight — Institutional Review Board oversight is required for administration under this pathway
• ✓Approved facility — must be administered at a hospital, medical school, or registered outpatient facility

HB 5147 — 2025 Update

Texas HB 5147, effective September 2025, significantly expanded the HB 810 framework. The most important changes for Texas practitioners:

• Outpatient settings added — physicians can now administer under HB 810 at registered outpatient facilities, not just hospitals and medical schools
• Physician registration — physicians must register with the Texas Medical Board to use the outpatient pathway
• Annual adverse event reporting — IRBs are now required to submit annual adverse event reports to the Texas Medical Board

Exosome Biologics in Texas — Topical Cosmetic Only

Texas law does not create a therapeutic authorization for exosome biologics specifically. Exosome biologics in Texas — as in all 50 states — must be positioned and used as topical cosmetic products only, with no disease claims, no therapeutic claims, and no injectable use under any state law framework. The only compliant lane for exosome biologics in Texas is topical cosmetic application at licensed aesthetic and medical practices.

Texas's Regenerative Medicine Market — By Practice Vertical

Texas has one of the largest and most geographically diverse licensed practitioner markets in the country. The four major metro areas represent distinct practice concentrations and biologic demand profiles.

Why Texas Practitioners Are Evaluating Exosome Biologics

For Medspas and Aesthetic Practices

Texas has one of the most competitive aesthetic medicine markets in the country. The DFW corridor alone has hundreds of licensed medspas competing for the same patient base. Practices that differentiated on microneedling five years ago, then PRP three years ago, are now looking for the next premium tier. Topical cosmetic exosome biologics represent that tier — delivering session values of $1,500–$3,000 without new equipment investment, phlebotomy, or centrifuge setup.

The most common medspa applications in Texas practices: post-microneedling topical application, post-laser resurfacing recovery support, professional facial rejuvenation protocols, and hair restoration scalp treatments.

For Orthopedic, Pain, and Sports Medicine Physicians

Texas has a disproportionately large sports medicine and orthopedic physician base — driven by a massive recreational and professional sports culture across all four major metros. Licensed physicians operating under HB 810 and HB 5147 with appropriate IRB oversight are evaluating UCT-MSC biologics for tendinopathy, joint pathology, and post-surgical adjunct protocols.

Texas's Right to Try + investigational framework means qualified physicians have a defined legal pathway for these applications — but it requires physician registration, IRB oversight, and documented clinical trial basis for the specific biologic being used.

For Wellness and Longevity Practices

The Austin and Houston wellness markets have developed significant demand for IV-based and systemic wellness protocols. UCT-MSC biologics are being evaluated in this context as a premium tier above peptides and NAD+ — positioned around immunomodulatory support and cellular health signaling rather than any disease claim.

What Texas Practitioners Should Require from a Biologic Supplier

The supplier documentation standard in Texas is the same as any other state — and for HB 810/5147 compliance, documentation becomes especially important since IRB oversight requires traceable sourcing records.

• ✓AATB Accreditation — American Association of Tissue Banks accreditation from the manufacturing facility. This is the industry-recognized quality standard and is legally required by Florida SB 1768 (relevant for multi-state practices). Verify the accreditation directly — not just from the supplier's marketing materials.
• ✓FDA-Registered Tissue Establishment — operating under cGTP standards per 21 CFR Part 1271. Not cGMP — that standard applies to pharmaceutical drugs, not HCT/P tissue products.
• ✓Lot-Specific Certificate of Analysis — must cover NTA-verified particle count, post-thaw viability, flow cytometry (CD90/CD166 ≥80%), sterility, mycoplasma, endotoxin, and full 9-marker viral panel on the specific lot you receive. Not a reference lot. Not estimated figures.
• ✓First-Pregnancy Donor Restriction — for UCT-MSC biologics, first-pregnancy donors provide the youngest, least immunologically conditioned Wharton's jelly tissue available. This is a sourcing quality differentiator not universally applied across the supplier market.
• ✓Verified Particle Count via NTA — Nanoparticle Tracking Analysis (ZetaView or equivalent) is the gold standard for confirming actual particle count in the vial. Generic concentration claims without instrument-verified NTA data are marketing, not documentation.
• ✓Texas-compatible storage and cold chain — Texas summer temperatures make cold chain integrity especially critical. Verify that your supplier ships on dry ice with validated packaging and that you have -80°C storage in place before your first order.

Why Sourcing from a Texas-Based Supplier Matters

Stem Nova Network is based in Spring, Texas — 22924 Kuykendahl Road, Suite B, Spring, TX 77389. As a Texas-based wholesale supplier, we offer several advantages for Texas practitioners specifically:

Texas Supplier Evaluation Checklist for Licensed Practitioners

Before committing to any exosome or UCT-MSC biologic supplier in Texas, verify the following directly — not from a product landing page:

Frequently Asked Questions — Texas Practitioners